Association between psoriasis severity and transforming growth factor β1 and β2 in plasma and scales from psoriatic lesions

Cytokine

Volumn 19, Issue 3, 2002, Pages 121-125

  Flisiak, Iwona ^a   Chodynicka, Bozena ^a   Porebski, Piotr ^a   Flisiak, Robert ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Psoriasis; Psoriasis activity and severity index; Transforming growth factor 1

Indexed keywords

PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PSORIASIS; SEDIMENTATION RATE;

EID: 0036403015     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2002.1953     Document Type: Article

References (24)

1. Kapp A (1993). The role of cytokines in the psoriatic inflammation. J Dermatol Sci 5:133-142.
2. Krueger JG, Krane JF, Carter DM, Gottlieb AB (1990). Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 94 (6 suppl): 135-140.
3. Borkowski TA, Letterio JJ, Farr AG, Udey MCA (1996). A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med 184: 2417-2422.
4. Kane CJ, Knapp AM, Mansbridge JN, Hanawalt PC (1990). Transforming growth factor-beta 1 localization in normal and psoriatic epidermal keratinocytes in situ. J Cell Physiol 144: 144-150.
5. Gold LI, Jussila T, Fusenig NE, Stenback F (2000). TGF-beta isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. J Pathol 190: 579-588.
6. Singer AJ, Clark RAF (1999). Cutaneous Wound Healing. N Engl J Med 341: 738-746.
7. Furue M, Kato M, Nakamura K, Nashiro K, Kikuchi K, Okochi H, Miyazono K, Tamaki K (1997). Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. Int J Cancer 71:505-509.
8. Leivo T, Leivo I, Kariniemi AL, Keski-Oja J, Virtanen I (1998). Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. Br J Dermatol 138: 57-62.
9. Wang XJ, Greenhalgh DA, Bickenbach JR, Jiang A, Bundman DS, Krieg T, Derynck R, Roop DR (1997). Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci U S A 94:2386-2391.
10. Wataya-Kaneda M, Hashimoto K, Kato M, Miyazono K, Yoshikawa K (1996). Differential localization of TGF-beta-precursor isotypes in psoriatic human skin. J Dermatol Sci 11: 183-188.
11. Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor γ in human diseases. N Engl J Med 342: 1350-1358.
12. Kondo S, Hozumi Y, Maejima H, Aso K (1992). Organ culture of psoriatic skin: effect of TGF-alpha and TGF-beta on epidermal structure in vitro. Arch Dermatol Res 284: 150-153.
13. Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, Narog B, Gazit A, Harzstark Z, Chaouat M, Levitzki R, Tang C, McMahon J, Shawver L, Levitzki A (1999). Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 141: 802-810.
14. Kadunce DP, Krueger GG (1995). Pathogenesis of psoriasis. Dermatol Clin 13:723-737.
15. Werner S, Beer HD, Mauch C, Luscher B, Werner S (2002). The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound healing and psoriasis. Oncogene 8: 7494-7504.
16. Grainger DJ, Mosedale DE, Metcalfe JC (2000). TGF-γ in blood: a complex problem. Cytokine & Growth Factor Rev 11: 133-145.
17. 1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 12: 677-681.
18. 1. Cytokine 14: 343-346.
19. Oyama N, Iwatsuki K, Satoh M, Akiba H, Kaneko F (2000). Dermal fibroblasts are one of the therapeutic targets for topical application of 1alpha,25-dihydroxyvitamin D3: the possible involvement of transforming growth factor-beta induction. Br J Dermatol 143:1140-1148.
20. Matsuura H, Myokai F, Arata J, Noji S, Taniguchi S (1994). Expression of type II transforming growth factor-beta receptor mRNA in human skin, as revealed by in situ hybridization. J Dermatol Sci 8: 25-32.
21. Cai JP, Falanga V, Taylor JR, Chin YH (1996). Transforming growth factor-beta receptor binding and function are decreased in psoriatic dermal endothelium. J Invest Dermatol 106: 225-231.
22. Fredriksson T, Pettersson U (1978). Severe psoriasis - oral therapy with a new retinoid. Dermatologica 157: 238-244.
23. Thompson M, Feutren G (1997). Psoriasis area and severity index. Novartis Pharma AG, Basel.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.